Image
Xolair banner
Xolair autoinjector demo video VIDEO

Demonstration Trainer video for HCP training only. 

Adverse events: Very common (210%) headache. Common to <10%)- sinusitis, viral upper respiratory tract infection, arthralgia. Please review the Product Information for the full list of adverse event.

PBS Information: Section 100 Public and Private Hospital Authority Required for the treatment of severe allergic asthma in patients aged at least 6 years, and for the treatment of severe chronic spontaneous urticaria. Refer to PBS Schedule for full authority information. Treatment of severe chronic rhinosinusitis with nasal polyps not listed on the PBS.

For healthcare professionals only. Please review full Product information here before prescribing 

References: 1. ARTG. Xolair 300 mg Solution for Injection Pre-filled Pen Public Summary Document. 

Video veeva number AU-28490. Date of preparation: July 2025.